FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer

PURPOSE: Because of its aggressive characteristics and poor prognosis, triple-negative breast cancer (TNBC) has become a hot topic in cancer research. Chemotherapy is currently the only treatment for patients with TNBC. The transcription factor FOXC1 has been associated with TNBC prognosis, but litt...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Y. L., Yao, R., Li, J., Zhou, Y. D., Mao, F., Pan, B., Sun, Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438824/
https://www.ncbi.nlm.nih.gov/pubmed/28493031
http://dx.doi.org/10.1007/s00280-017-3319-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438824/
https://www.ncbi.nlm.nih.gov/pubmed/28493031
http://dx.doi.org/10.1007/s00280-017-3319-4

Ejemplares similares